Press Kit

The Problem

• Decrease in new classes of antibiotics and new drug approvals • Increase in number of bacteria resistant to antibiotics

• According to the Center for Disease Control: 2 million infected each year in USA with multidrug resistance bacteria resulting in 23,000 and over 700,000 deaths world wide • By 2050 it is estimated there will be 10 million deaths per year, this is an estimate based on a United Kingdom government report: A Review on Antimicrobial Resistance • The World Health Organization (WHO) published a list of 12 bacterial pathogens for which new antibiotics are urgently needed due to the lack of antibiotic drug development

Techulon develops antimicrobial drugs to fill this unmet clinical need by specifically targeting bacterial genes of critical function Platform Technology:

 Rational Design  Pathogen specific  Rapid Discovery

 Modular  Scalable

Techulon currently has three drug candidates in preclinical development that target the WHO’s critical priority list of bacterial pathogens: Acinetobacter baumannii , Pseudomonas aeruginosa and Klebsiella pneumoniae